newsfilter
← Latest News
GlobeNewswire·

HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023

HB-200 monotherapy induced a robust increase in circulating tumor-specific CD8+ T cells in all evaluable Phase 1 patients with heavily pretreated HPV16+ head and neck cancer T cell responses were high quality, durable